Live Now: E-DICE-R (64/020,559) + MindNetQ (63/914,248) running end-to-end cancer biomarker workflows in the cloud, with broader platform experience expanding for partners and customers.

Research brief

Live cancer workflows and biomarker discovery.

This page provides a cleaner summary of the broader research direction without exposing internal logic. It highlights live testing, the current biomarker focus, and the broader multi-omics context in a concise, investor-friendly format.

Live statusE-DICE-R and MindNetQ are currently running end-to-end cancer biomarker workflows in the cloud.
Current phaseBiomarker discovery and validation focused on stable, reproducible molecular signals.
Multi-omics contextThe program supports structured research across multiple data types and review stages.

What is happening now

MindNetQ is being applied to complex biomedical problems including cancer biomarker discovery and multi-omics analysis. The current emphasis is live testing, candidate review, and repeatable research validation.

  • Live cloud-based cancer workflow testing
  • Biomarker and pathway candidate review
  • High-level control before downstream use

What this supports

Teams can explore promising signals, review outputs with more confidence, and prepare for later stages of research expansion.

  • Clearer candidate prioritization
  • Reduced false positives
  • More confidence before escalation

Research focus

We are starting with biomarker discovery and validation. After performance is validated through testing, the roadmap expands into broader patient-level analysis and downstream research applications.

Public-safe summary

This page intentionally stays high-level. It avoids deep system details and proprietary mechanics while still communicating the importance of the live research work and the broader commercial direction.